Vir Biotechnology, Inc. (VIR) saw its stock surge 8.02% in pre-market trading on Wednesday, following the announcement of significant progress in its chronic hepatitis delta (CHD) treatment program. The biotechnology company has successfully initiated all trials in its ECLIPSE registrational program, marking a major milestone in its efforts to address this serious liver disease.

The company reported the enrollment of the first participant in ECLIPSE 3, a Phase 2b trial that forms a crucial part of the registrational program. This trial aims to compare the combination treatment of tobevibart and elebsiran with bulevirtide in CHD patients. The ECLIPSE program is designed to provide supportive data for establishing access and reimbursement in key markets, potentially paving the way for a new treatment option for CHD patients.

Investors appear to be responding positively to this development, recognizing the potential impact of Vir Biotechnology's innovative approach to treating chronic hepatitis delta. The combination therapy of tobevibart and elebsiran has already received several designations from regulatory agencies, highlighting its potential in addressing unmet medical needs in CHD. While the results of these trials are yet to be presented, the successful initiation of the entire ECLIPSE program signals a significant step forward in Vir Biotechnology's clinical development efforts.